ID   MYC_HUMAN               Reviewed;         454 AA.
AC   P01106; A0A024R9L7; A0A087WUS5; A8WFE7; H0YBT0; P01107; Q14026;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   22-FEB-2023, sequence version 2.
DT   18-JUN-2025, entry version 279.
DE   RecName: Full=Myc proto-oncogene protein;
DE   AltName: Full=Class E basic helix-loop-helix protein 39;
DE            Short=bHLHe39;
DE   AltName: Full=Proto-oncogene c-Myc;
DE   AltName: Full=Transcription factor p64;
GN   Name=MYC; Synonyms=BHLHE39;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6414718; DOI=10.1016/0092-8674(83)90534-2;
RA   Battey J., Moulding C., Taub R., Murphy W., Stewart T., Potter H.,
RA   Lenoir G., Leder P.;
RT   "The human c-myc oncogene: structural consequences of translocation into
RT   the IgH locus in Burkitt lymphoma.";
RL   Cell 34:779-787(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6321164; DOI=10.1002/j.1460-2075.1983.tb01749.x;
RA   Bernard O., Cory S., Gerondakis S., Webb E., Adams J.M.;
RT   "Sequence of the murine and human cellular myc oncogenes and two modes of
RT   myc transcription resulting from chromosome translocation in B lymphoid
RT   tumours.";
RL   EMBO J. 2:2375-2383(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6298632; DOI=10.1038/301722a0;
RA   Colby W.W., Chen E.Y., Smith D.H., Levinson A.D.;
RT   "Identification and nucleotide sequence of a human locus homologous to the
RT   v-myc oncogene of avian myelocytomatosis virus MC29.";
RL   Nature 301:722-725(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6304538; DOI=10.1038/303725a0;
RA   Watt R., Stanton L.W., Marcu K.B., Gallo R.C., Croce C.M., Rovera G.;
RT   "Nucleotide sequence of cloned cDNA of human c-myc oncogene.";
RL   Nature 303:725-728(1983).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-54.
RX   PubMed=6419122; DOI=10.1038/306760a0;
RA   Rabbitts T.H., Hamlyn P.H., Baer R.;
RT   "Altered nucleotide sequences of a translocated c-myc gene in Burkitt
RT   lymphoma.";
RL   Nature 306:760-765(1983).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6304729; DOI=10.1073/pnas.80.12.3642;
RA   Watson D.K., Psallidopoulos M.C., Samuel K.P., Dalla-Favera R., Papas T.S.;
RT   "Nucleotide sequence analysis of human c-myc locus, chicken homologue, and
RT   myelocytomatosis virus MC29 transforming gene reveals a highly conserved
RT   gene product.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3642-3645(1983).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE [GENOMIC
RP   DNA] OF 16-267.
RX   PubMed=6547209; DOI=10.1038/309592a0;
RA   Rabbitts T.H., Forster A., Hamlyn P., Baer R.;
RT   "Effect of somatic mutation within translocated c-myc genes in Burkitt's
RT   lymphoma.";
RL   Nature 309:592-597(1984).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6714223; DOI=10.1002/j.1460-2075.1984.tb01816.x;
RA   Gazin C., Dupont S., de Dinechin D., Hampe A., Masson J.-M., Martin P.,
RA   Stehelin D., Galibert F.;
RT   "Nucleotide sequence of the human c-myc locus: provocative open reading
RT   frame within the first exon.";
RL   EMBO J. 3:383-387(1984).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8444346; DOI=10.1016/0378-1119(93)90398-m;
RA   Tachibana K., Takayama N., Matsuo K., Kato S., Yamamoto K., Ohyama K.,
RA   Umezawa A., Takano T.;
RT   "Allele-specific activation of the c-myc gene in an atypical Burkitt's
RT   lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream
RT   from c-myc.";
RL   Gene 124:231-237(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-26; CYS-175; ILE-185
RP   AND VAL-337.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cervix, Placenta, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-185 (ISOFORM 1).
RC   TISSUE=Promyelocytic leukemia;
RX   PubMed=3540591; DOI=10.1128/mcb.6.10.3481-3489.1986;
RA   Bentley D.L., Groudine M.;
RT   "Novel promoter upstream of the human c-myc gene and regulation of c-myc
RT   expression in B-cell lymphomas.";
RL   Mol. Cell. Biol. 6:3481-3489(1986).
RN   [17]
RP   ALTERNATIVE TRANSLATION INITIATION.
RX   PubMed=3277717; DOI=10.1016/0092-8674(88)90507-7;
RA   Hann S.R., King M.W., Bentley D.L., Anderson C.W., Eisenman R.N.;
RT   "A non-AUG translational initiation in c-myc exon 1 generates an N-
RT   terminally distinct protein whose synthesis is disrupted in Burkitt's
RT   lymphomas.";
RL   Cell 52:185-195(1988).
RN   [18]
RP   INVOLVEMENT IN BURKITT LYMPHOMA.
RX   PubMed=2166998; DOI=10.1016/s0065-230x(08)60470-4;
RA   Magrath I.;
RT   "The pathogenesis of Burkitt's lymphoma.";
RL   Adv. Cancer Res. 55:133-270(1990).
RN   [19]
RP   PHOSPHORYLATION.
RX   PubMed=1597196; DOI=10.1111/j.1432-1033.1992.tb16964.x;
RA   Iijima S., Teraoka H., Date T., Tsukada K.;
RT   "DNA-activated protein kinase in Raji Burkitt's lymphoma cells.
RT   Phosphorylation of c-Myc oncoprotein.";
RL   Eur. J. Biochem. 206:595-603(1992).
RN   [20]
RP   INVOLVEMENT IN BURKITT LYMPHOMA, AND VARIANTS ASP-54; SER-72; ALA-74 AND
RP   THR-101.
RX   PubMed=8220424; DOI=10.1038/ng0993-56;
RA   Bhatia K., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.;
RT   "Point mutations in the c-Myc transactivation domain are common in
RT   Burkitt's lymphoma and mouse plasmacytomas.";
RL   Nat. Genet. 5:56-61(1993).
RN   [21]
RP   PHOSPHORYLATION AT THR-73 AND SER-77.
RX   PubMed=8386367; DOI=10.1073/pnas.90.8.3216;
RA   Gupta S., Seth A., Davis R.J.;
RT   "Transactivation of gene expression by Myc is inhibited by mutation at the
RT   phosphorylation sites Thr-73 and Ser-77.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3216-3220(1993).
RN   [22]
RP   GLYCOSYLATION AT THR-73.
RX   PubMed=7642555; DOI=10.1074/jbc.270.32.18961;
RA   Chou T.-Y., Hart G.W., Dang C.V.;
RT   "c-Myc is glycosylated at threonine 58, a known phosphorylation site and a
RT   mutational hot spot in lymphomas.";
RL   J. Biol. Chem. 270:18961-18965(1995).
RN   [23]
RP   PHOSPHORYLATION AT THR-23.
RX   PubMed=9315742; DOI=10.1016/s0014-5793(97)00992-7;
RA   Alexandrov I., Shlyakhova L., Vartanian A., Zajac-Kaye M., Alexandrova N.;
RT   "c-Raf kinase binds to N-terminal domain of c-Myc.";
RL   FEBS Lett. 414:465-470(1997).
RN   [24]
RP   UBIQUITINATION, INTERACTION WITH FBXW7, PHOSPHORYLATION AT THR-73 AND
RP   SER-77, AND MUTAGENESIS OF THR-73 AND SER-77.
RX   PubMed=15103331; DOI=10.1038/sj.emboj.7600217;
RA   Yada M., Hatakeyama S., Kamura T., Nishiyama M., Tsunematsu R., Imaki H.,
RA   Ishida N., Okumura F., Nakayama K., Nakayama K.I.;
RT   "Phosphorylation-dependent degradation of c-Myc is mediated by the F-box
RT   protein Fbw7.";
RL   EMBO J. 23:2116-2125(2004).
RN   [25]
RP   ACETYLATION AT LYS-158; LYS-172; LYS-290; LYS-332; LYS-338 AND LYS-386, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16126174; DOI=10.1016/j.bbrc.2005.08.075;
RA   Zhang K., Faiola F., Martinez E.;
RT   "Six lysine residues on c-Myc are direct substrates for acetylation by
RT   p300.";
RL   Biochem. Biophys. Res. Commun. 336:274-280(2005).
RN   [26]
RP   INTERACTION WITH TAF1C.
RX   PubMed=15723054; DOI=10.1038/ncb1224;
RA   Grandori C., Gomez-Roman N., Felton-Edkins Z.A., Ngouenet C.,
RA   Galloway D.A., Eisenman R.N., White R.J.;
RT   "c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA
RT   genes by RNA polymerase I.";
RL   Nat. Cell Biol. 7:311-318(2005).
RN   [27]
RP   INTERACTION WITH PARP10.
RX   PubMed=15674325; DOI=10.1038/sj.onc.1208410;
RA   Yu M., Schreek S., Cerni C., Schamberger C., Lesniewicz K., Poreba E.,
RA   Vervoorts J., Walsemann G., Groetzinger J., Kremmer E., Mehraein Y.,
RA   Mertsching J., Kraft R., Austen M., Luescher-Firzlaff J., Luescher B.;
RT   "PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase
RT   activity, inhibits transformation.";
RL   Oncogene 24:1982-1993(2005).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-73, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [29]
RP   INTERACTION WITH CIP2A.
RX   PubMed=17632056; DOI=10.1016/j.cell.2007.04.044;
RA   Junttila M.R., Puustinen P., Niemelae M., Ahola R., Arnold H.,
RA   Boettzauw T., Ala-Aho R., Nielsen C., Ivaska J., Taya Y., Lu S.-L., Lin S.,
RA   Chan E.K.L., Wang X.-J., Grenman R., Kast J., Kallunki T., Sears R.,
RA   Kaehaeri V.-M., Westermarck J.;
RT   "CIP2A inhibits PP2A in human malignancies.";
RL   Cell 130:51-62(2007).
RN   [30]
RP   BIOTECHNOLOGY.
RX   PubMed=18035408; DOI=10.1016/j.cell.2007.11.019;
RA   Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K.,
RA   Yamanaka S.;
RT   "Induction of pluripotent stem cells from adult human fibroblasts by
RT   defined factors.";
RL   Cell 131:861-872(2007).
RN   [31]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP28, AND INTERACTION WITH FBXW7.
RX   PubMed=17873522; DOI=10.4161/cc.6.19.4804;
RA   Popov N., Herold S., Llamazares M., Schulein C., Eilers M.;
RT   "Fbw7 and Usp28 regulate myc protein stability in response to DNA damage.";
RL   Cell Cycle 6:2327-2331(2007).
RN   [32]
RP   INTERACTION WITH KDM5A AND KDM5B.
RX   PubMed=17311883; DOI=10.1101/gad.1523007;
RA   Secombe J., Li L., Carlos L., Eisenman R.N.;
RT   "The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase
RT   required for dMyc-induced cell growth.";
RL   Genes Dev. 21:537-551(2007).
RN   [33]
RP   INTERACTION WITH RIOX1.
RX   PubMed=17308053; DOI=10.1158/1535-7163.mct-06-0659;
RA   Suzuki C., Takahashi K., Hayama S., Ishikawa N., Kato T., Ito T.,
RA   Tsuchiya E., Nakamura Y., Daigo Y.;
RT   "Identification of Myc-associated protein with JmjC domain as a novel
RT   therapeutic target oncogene for lung cancer.";
RL   Mol. Cancer Ther. 6:542-551(2007).
RN   [34]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP28, INTERACTION WITH FBXW7,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-73 AND SER-77, AND MUTAGENESIS
RP   OF THR-73 AND SER-77.
RX   PubMed=17558397; DOI=10.1038/ncb1601;
RA   Popov N., Wanzel M., Madiredjo M., Zhang D., Beijersbergen R., Bernards R.,
RA   Moll R., Elledge S.J., Eilers M.;
RT   "The ubiquitin-specific protease USP28 is required for MYC stability.";
RL   Nat. Cell Biol. 9:765-774(2007).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-73; SER-77 AND SER-86, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [37]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-163, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [38]
RP   REVIEW ON SENESCENCE, PHOSPHORYLATION AT SER-77 BY CDK2, AND MUTAGENESIS OF
RP   THR-73 AND SER-77.
RX   PubMed=20713526; DOI=10.1158/0008-5472.can-10-1383;
RA   Hydbring P., Larsson L.-G.;
RT   "Tipping the balance: Cdk2 enables Myc to suppress senescence.";
RL   Cancer Res. 70:6687-6691(2010).
RN   [39]
RP   FUNCTION.
RX   PubMed=20010808; DOI=10.1038/nature08697;
RA   David C.J., Chen M., Assanah M., Canoll P., Manley J.L.;
RT   "HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA
RT   splicing in cancer.";
RL   Nature 463:364-368(2010).
RN   [40]
RP   PHOSPHORYLATION AT SER-77 BY CDK2, AND MUTAGENESIS OF THR-73 AND SER-77.
RX   PubMed=19966300; DOI=10.1073/pnas.0900121106;
RA   Hydbring P., Bahram F., Su Y., Tronnersjoe S., Hoegstrand K.,
RA   von der Lehr N., Sharifi H.R., Lilischkis R., Hein N., Wu S., Vervoorts J.,
RA   Henriksson M., Grandien A., Luescher B., Larsson L.-G.;
RT   "Phosphorylation by Cdk2 is required for Myc to repress Ras-induced
RT   senescence in cotransformation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:58-63(2010).
RN   [41]
RP   UBIQUITINATION.
RX   PubMed=20551172; DOI=10.1101/gad.1920310;
RA   Choi S.H., Wright J.B., Gerber S.A., Cole M.D.;
RT   "Myc protein is stabilized by suppression of a novel E3 ligase complex in
RT   cancer cells.";
RL   Genes Dev. 24:1236-1241(2010).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND SER-176, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-73 AND SER-77, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [44]
RP   INTERACTION WITH NUP205, AND SUBCELLULAR LOCATION.
RX   PubMed=22719065; DOI=10.1158/0008-5472.can-12-0159;
RA   Fujitomo T., Daigo Y., Matsuda K., Ueda K., Nakamura Y.;
RT   "Critical function for nuclear envelope protein TMEM209 in human pulmonary
RT   carcinogenesis.";
RL   Cancer Res. 72:4110-4118(2012).
RN   [45]
RP   PHOSPHORYLATION AT SER-77, AND MUTAGENESIS OF SER-77.
RX   PubMed=22307329; DOI=10.1172/jci60818;
RA   Taira N., Mimoto R., Kurata M., Yamaguchi T., Kitagawa M., Miki Y.,
RA   Yoshida K.;
RT   "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle
RT   progression in human cancer cells.";
RL   J. Clin. Invest. 122:859-872(2012).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; THR-73; SER-77; SER-86
RP   AND SER-308, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   FUNCTION.
RX   PubMed=24940000; DOI=10.7554/elife.02349;
RA   Shi Y., Xu X., Zhang Q., Fu G., Mo Z., Wang G.S., Kishi S., Yang X.L.;
RT   "tRNA synthetase counteracts c-Myc to develop functional vasculature.";
RL   Elife 3:E02349-E02349(2014).
RN   [48]
RP   FUNCTION, AND INTERACTION WITH NPM1.
RX   PubMed=25956029; DOI=10.1016/j.ajpath.2015.03.016;
RA   Kim J.Y., Cho Y.E., Park J.H.;
RT   "The nucleolar protein GLTSCR2 is an upstream negative regulator of the
RT   oncogenic Nucleophosmin-MYC axis.";
RL   Am. J. Pathol. 185:2061-2068(2015).
RN   [49]
RP   PHOSPHORYLATION AT SER-77.
RX   PubMed=25803737; DOI=10.1080/15384101.2015.1021526;
RA   Cianfanelli V., D'Orazio M., Cecconi F.;
RT   "AMBRA1 and BECLIN 1 interplay in the crosstalk between autophagy and cell
RT   proliferation.";
RL   Cell Cycle 14:959-963(2015).
RN   [50]
RP   PHOSPHORYLATION AT SER-77, DEPHOSPHORYLATION, AND MUTAGENESIS OF SER-77.
RX   PubMed=25438055; DOI=10.1038/ncb3072;
RA   Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F.,
RA   Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T.,
RA   Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C.,
RA   Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G.,
RA   Cecconi F.;
RT   "AMBRA1 links autophagy to cell proliferation and tumorigenesis by
RT   promoting c-Myc dephosphorylation and degradation.";
RL   Nat. Cell Biol. 17:20-30(2015).
RN   [51]
RP   ERRATUM OF PUBMED:25438055.
RX   PubMed=25925585; DOI=10.1038/ncb3171;
RA   Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F.,
RA   Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T.,
RA   Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C.,
RA   Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G.,
RA   Cecconi F.;
RL   Nat. Cell Biol. 17:706-706(2015).
RN   [52]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP36, INTERACTION WITH FBXW7, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=25775507; DOI=10.1073/pnas.1411713112;
RA   Sun X.X., He X., Yin L., Komada M., Sears R.C., Dai M.S.;
RT   "The nucleolar ubiquitin-specific protease USP36 deubiquitinates and
RT   stabilizes c-Myc.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:3734-3739(2015).
RN   [53]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-67; LYS-158; LYS-163 AND LYS-313,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [54]
RP   UBIQUITINATION, AND MUTAGENESIS OF ARG-450.
RX   PubMed=29779948; DOI=10.1016/j.cell.2018.04.028;
RA   Koren I., Timms R.T., Kula T., Xu Q., Li M.Z., Elledge S.J.;
RT   "The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting C-
RT   terminal degrons.";
RL   Cell 173:1622-1635(2018).
RN   [55]
RP   UBIQUITINATION, PHOSPHORYLATION AT THR-73; SER-77; SER-86; SER-96; SER-166;
RP   SER-174; SER-176; SER-329; THR-330; SER-359; SER-362 AND SER-363,
RP   DEPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=30158517; DOI=10.1038/s41467-018-05660-0;
RA   Dingar D., Tu W.B., Resetca D., Lourenco C., Tamachi A., De Melo J.,
RA   Houlahan K.E., Kalkat M., Chan P.K., Boutros P.C., Raught B., Penn L.Z.;
RT   "MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates
RT   chromatin binding and protein stability.";
RL   Nat. Commun. 9:3502-3502(2018).
RN   [56]
RP   UBIQUITINATION.
RX   PubMed=33208877; DOI=10.1038/s41598-020-76960-z;
RA   Schukur L., Zimmermann T., Niewoehner O., Kerr G., Gleim S.,
RA   Bauer-Probst B., Knapp B., Galli G.G., Liang X., Mendiola A.,
RA   Reece-Hoyes J., Rapti M., Barbosa I., Reschke M., Radimerski T.,
RA   Thoma C.R.;
RT   "Identification of the HECT E3 ligase UBR5 as a regulator of MYC
RT   degradation using a CRISPR/Cas9 screen.";
RL   Sci. Rep. 10:20044-20044(2020).
RN   [57]
RP   9AATAD MOTIF.
RX   PubMed=34342803; DOI=10.1007/s12015-021-10225-8;
RA   Piskacek M., Otasevic T., Repko M., Knight A.;
RT   "The 9aaTAD Activation Domains in the Yamanaka Transcription Factors Oct4,
RT   Sox2, Myc, and Klf4.";
RL   Stem. Cell. Rev. Rep. 17:1934-1936(2021).
RN   [58]
RP   UBIQUITINATION.
RX   PubMed=37478862; DOI=10.1016/j.cell.2023.06.015;
RA   Mark K.G., Kolla S., Aguirre J.D., Garshott D.M., Schmitt S.,
RA   Haakonsen D.L., Xu C., Kater L., Kempf G., Martinez-Gonzalez B.,
RA   Akopian D., See S.K., Thomae N.H., Rape M.;
RT   "Orphan quality control shapes network dynamics and gene expression.";
RL   Cell 186:3460-3475(2023).
RN   [59]
RP   INTERACTION WITH HEATR1, AND SUBCELLULAR LOCATION.
RX   PubMed=38225354; DOI=10.1038/s44319-023-00017-1;
RA   Diaz L.R., Gil-Ranedo J., Jaworek K.J., Nsek N., Marques J.P., Costa E.,
RA   Hilton D.A., Bieluczyk H., Warrington O., Hanemann C.O., Futschik M.E.,
RA   Bossing T., Barros C.S.;
RT   "Ribogenesis boosts controlled by HEATR1-MYC interplay promote transition
RT   into brain tumour growth.";
RL   EMBO Rep. 25:168-197(2024).
RN   [60]
RP   STRUCTURE BY NMR OF 417-449 IN COMPLEX WITH MAX.
RX   PubMed=9680483; DOI=10.1006/jmbi.1998.1914;
RA   Lavigne P., Crump M.P., Gagne S.M., Hodges R.S., Kay C.M., Sykes B.D.;
RT   "Insights into the mechanism of heterodimerization from the 1H-NMR solution
RT   structure of the c-Myc-Max heterodimeric leucine zipper.";
RL   J. Mol. Biol. 281:165-181(1998).
RN   [61]
RP   CHROMOSOMAL TRANSLOCATION WITH BTG1.
RX   PubMed=2069907; DOI=10.1002/gcc.2870030106;
RA   Rimokh R., Rouault J.P., Wahbi K., Gadoux M., Lafage M., Archimbaud E.,
RA   Charrin C., Gentilhomme O., Germain D., Samarut J.;
RT   "A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus
RT   in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic
RT   leukemia.";
RL   Genes Chromosomes Cancer 3:24-36(1991).
CC   -!- FUNCTION: Transcription factor that binds DNA in a non-specific manner,
CC       yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'
CC       (PubMed:24940000, PubMed:25956029). Activates the transcription of
CC       growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the
CC       VEGFA promoter, promoting VEGFA production and subsequent sprouting
CC       angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic
CC       reprogramming, controls self-renewal of embryonic stem cells (By
CC       similarity). Functions with TAF6L to activate target gene expression
CC       through RNA polymerase II pause release (By similarity). Positively
CC       regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn
CC       regulate splicing of pyruvate kinase PKM by binding repressively to
CC       sequences flanking PKM exon 9, inhibiting exon 9 inclusion and
CC       resulting in exon 10 inclusion and production of the PKM M2 isoform
CC       (PubMed:20010808). {ECO:0000250|UniProtKB:P01108,
CC       ECO:0000269|PubMed:20010808, ECO:0000269|PubMed:24940000,
CC       ECO:0000269|PubMed:25956029}.
CC   -!- SUBUNIT: Efficient DNA binding requires dimerization with another bHLH
CC       protein. Binds DNA as a heterodimer with MAX (PubMed:9680483).
CC       Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with
CC       KDM5A and KDM5B. Interacts (when phosphorylated at Thr-73 and Ser-77)
CC       with FBXW7 (PubMed:17558397, PubMed:25775507). Interacts with PIM2.
CC       Interacts with RIOX1. The heterodimer MYC:MAX interacts with ABI1; the
CC       interaction may enhance MYC:MAX transcriptional activity. Interacts
CC       with TRIM6 (By similarity). Interacts with NPM1; the binary complex is
CC       recruited to the promoter of MYC target genes and enhances their
CC       transcription (PubMed:25956029). Interacts with CIP2A; leading to the
CC       stabilization of MYC (PubMed:17632056). Interacts with NUP205
CC       (PubMed:22719065). Interacts with HEATR1; the interaction is required
CC       for localization of MYC to the nucleolus (PubMed:38225354).
CC       {ECO:0000250|UniProtKB:P01108, ECO:0000269|PubMed:15103331,
CC       ECO:0000269|PubMed:15674325, ECO:0000269|PubMed:15723054,
CC       ECO:0000269|PubMed:17308053, ECO:0000269|PubMed:17311883,
CC       ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:17632056,
CC       ECO:0000269|PubMed:17873522, ECO:0000269|PubMed:22719065,
CC       ECO:0000269|PubMed:25775507, ECO:0000269|PubMed:25956029,
CC       ECO:0000269|PubMed:38225354, ECO:0000269|PubMed:9680483}.
CC   -!- INTERACTION:
CC       P01106; Q9UBB4: ATXN10; NbExp=4; IntAct=EBI-447544, EBI-702390;
CC       P01106; O15169: AXIN1; NbExp=10; IntAct=EBI-447544, EBI-710484;
CC       P01106; O00499-10: BIN1; NbExp=3; IntAct=EBI-447544, EBI-7689134;
CC       P01106; O00499-11: BIN1; NbExp=2; IntAct=EBI-447544, EBI-7689211;
CC       P01106; Q15059: BRD3; NbExp=3; IntAct=EBI-447544, EBI-1383460;
CC       P01106; P55212: CASP6; NbExp=3; IntAct=EBI-447544, EBI-718729;
CC       P01106; P45973: CBX5; NbExp=3; IntAct=EBI-447544, EBI-78219;
CC       P01106; Q8N163: CCAR2; NbExp=8; IntAct=EBI-447544, EBI-355410;
CC       P01106; P06307: CCK; NbExp=3; IntAct=EBI-447544, EBI-6624398;
CC       P01106; A5D8W4: CDH1; NbExp=3; IntAct=EBI-447544, EBI-7793316;
CC       P01106; P11802: CDK4; NbExp=2; IntAct=EBI-447544, EBI-295644;
CC       P01106; Q86XR8: CEP57; NbExp=3; IntAct=EBI-447544, EBI-308614;
CC       P01106; P28329-3: CHAT; NbExp=3; IntAct=EBI-447544, EBI-25837549;
CC       P01106; Q14839: CHD4; NbExp=2; IntAct=EBI-447544, EBI-372916;
CC       P01106; O15111: CHUK; NbExp=3; IntAct=EBI-447544, EBI-81249;
CC       P01106; Q8TCG1: CIP2A; NbExp=2; IntAct=EBI-447544, EBI-1379376;
CC       P01106; Q01658: DR1; NbExp=3; IntAct=EBI-447544, EBI-750300;
CC       P01106; Q15029: EFTUD2; NbExp=5; IntAct=EBI-447544, EBI-357897;
CC       P01106; Q96L91: EP400; NbExp=6; IntAct=EBI-447544, EBI-399163;
CC       P01106; Q96L91-2: EP400; NbExp=2; IntAct=EBI-447544, EBI-15698003;
CC       P01106; Q969H0: FBXW7; NbExp=7; IntAct=EBI-447544, EBI-359574;
CC       P01106; Q8N3Y1: FBXW8; NbExp=3; IntAct=EBI-447544, EBI-914770;
CC       P01106; P22607: FGFR3; NbExp=3; IntAct=EBI-447544, EBI-348399;
CC       P01106; O43524: FOXO3; NbExp=3; IntAct=EBI-447544, EBI-1644164;
CC       P01106; P49841-2: GSK3B; NbExp=3; IntAct=EBI-447544, EBI-15870655;
CC       P01106; P06396: GSN; NbExp=3; IntAct=EBI-447544, EBI-351506;
CC       P01106; Q00403: GTF2B; NbExp=3; IntAct=EBI-447544, EBI-389564;
CC       P01106; Q9Y5Q9: GTF3C3; NbExp=4; IntAct=EBI-447544, EBI-1054873;
CC       P01106; Q92769: HDAC2; NbExp=2; IntAct=EBI-447544, EBI-301821;
CC       P01106; O15379: HDAC3; NbExp=6; IntAct=EBI-447544, EBI-607682;
CC       P01106; Q9Y6K9: IKBKG; NbExp=3; IntAct=EBI-447544, EBI-81279;
CC       P01106; O60341: KDM1A; NbExp=4; IntAct=EBI-447544, EBI-710124;
CC       P01106; O00629: KPNA4; NbExp=20; IntAct=EBI-447544, EBI-396343;
CC       P01106; P13473-2: LAMP2; NbExp=3; IntAct=EBI-447544, EBI-21591415;
CC       P01106; P61244: MAX; NbExp=46; IntAct=EBI-447544, EBI-751711;
CC       P01106; O95983: MBD3; NbExp=3; IntAct=EBI-447544, EBI-1783068;
CC       P01106; P33993: MCM7; NbExp=6; IntAct=EBI-447544, EBI-355924;
CC       P01106; A9UHW6: MIF4GD; NbExp=2; IntAct=EBI-447544, EBI-373498;
CC       P01106; P01106: MYC; NbExp=2; IntAct=EBI-447544, EBI-447544;
CC       P01106; O75928: PIAS2; NbExp=4; IntAct=EBI-447544, EBI-348555;
CC       P01106; Q13526: PIN1; NbExp=5; IntAct=EBI-447544, EBI-714158;
CC       P01106; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-447544, EBI-5280197;
CC       P01106; P62913: RPL11; NbExp=3; IntAct=EBI-447544, EBI-354380;
CC       P01106; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-447544, EBI-2623095;
CC       P01106; O75182: SIN3B; NbExp=7; IntAct=EBI-447544, EBI-540462;
CC       P01106; Q96EB6: SIRT1; NbExp=4; IntAct=EBI-447544, EBI-1802965;
CC       P01106; Q8N6T7: SIRT6; NbExp=3; IntAct=EBI-447544, EBI-712415;
CC       P01106; Q13309: SKP2; NbExp=2; IntAct=EBI-447544, EBI-456291;
CC       P01106; Q8TAD8: SNIP1; NbExp=9; IntAct=EBI-447544, EBI-749336;
CC       P01106; P08047: SP1; NbExp=4; IntAct=EBI-447544, EBI-298336;
CC       P01106; P31948: STIP1; NbExp=3; IntAct=EBI-447544, EBI-1054052;
CC       P01106; Q13148: TARDBP; NbExp=6; IntAct=EBI-447544, EBI-372899;
CC       P01106; P37173: TGFBR2; NbExp=3; IntAct=EBI-447544, EBI-296151;
CC       P01106; P11387: TOP1; NbExp=3; IntAct=EBI-447544, EBI-876302;
CC       P01106; Q14669: TRIP12; NbExp=7; IntAct=EBI-447544, EBI-308443;
CC       P01106; Q9Y4A5: TRRAP; NbExp=7; IntAct=EBI-447544, EBI-399128;
CC       P01106; P0CG48: UBC; NbExp=5; IntAct=EBI-447544, EBI-3390054;
CC       P01106; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-447544, EBI-741480;
CC       P01106; P17480: UBTF; NbExp=2; IntAct=EBI-447544, EBI-396235;
CC       P01106; Q13105: ZBTB17; NbExp=9; IntAct=EBI-447544, EBI-372156;
CC       P01106; Q9Y649; NbExp=3; IntAct=EBI-447544, EBI-25900580;
CC       P01106; P03129: E7; Xeno; NbExp=2; IntAct=EBI-447544, EBI-866453;
CC       P01106; P04020: E7; Xeno; NbExp=2; IntAct=EBI-447544, EBI-7005254;
CC       P01106; P06788: E7; Xeno; NbExp=5; IntAct=EBI-447544, EBI-1776887;
CC       P01106; P03204: EBNA6; Xeno; NbExp=11; IntAct=EBI-447544, EBI-9255985;
CC       P01106; P52164: Max; Xeno; NbExp=4; IntAct=EBI-447544, EBI-1184963;
CC       P01106; Q62141: Sin3b; Xeno; NbExp=8; IntAct=EBI-447544, EBI-591450;
CC       P01106; P03070; Xeno; NbExp=2; IntAct=EBI-447544, EBI-617698;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:17558397}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:25775507,
CC       ECO:0000269|PubMed:38225354}. Nucleus {ECO:0000269|PubMed:22719065,
CC       ECO:0000269|PubMed:38225354}. Cytoplasm {ECO:0000269|PubMed:22719065}.
CC       Chromosome {ECO:0000269|PubMed:30158517}. Note=Association with
CC       chromatin is reduced by hyperphosphorylation (PubMed:30158517).
CC       Localization to the nucleolus is dependent on HEATR1 (PubMed:38225354).
CC       {ECO:0000269|PubMed:30158517, ECO:0000269|PubMed:38225354}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=2; Synonyms=c-myc 1 {ECO:0000303|PubMed:3277717};
CC         IsoId=P01106-2; Sequence=Displayed;
CC       Name=1; Synonyms=c-myc 2 {ECO:0000303|PubMed:3277717};
CC         IsoId=P01106-1; Sequence=VSP_061778;
CC       Name=3;
CC         IsoId=P01106-3; Sequence=VSP_061779;
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:34342803}.
CC   -!- PTM: Phosphorylated by PRKDC (PubMed:1597196). Phosphorylation at Ser-
CC       344 by PIM2 leads to the stabilization of MYC (By similarity).
CC       Phosphorylation at Ser-77 by CDK2 prevents Ras-induced senescence
CC       (PubMed:19966300, PubMed:20713526). Phosphorylated at Ser-77 by DYRK2;
CC       this primes the protein for subsequent phosphorylation by GSK3B at Thr-
CC       73 (PubMed:22307329). Phosphorylation at Thr-73 and Ser-77 by GSK3 is
CC       required for ubiquitination and degradation by the proteasome
CC       (PubMed:15103331, PubMed:17558397, PubMed:8386367). Dephosphorylation
CC       at multiple sites by the PNUTS-PP1 complex promotes MYC stability by
CC       preventing ubiquitination by the SCF(FBXW7) complex (PubMed:30158517).
CC       Dephosphorylation at Ser-77 by protein phosphatase 2A (PPP2CA) promotes
CC       its degradation; interaction with PPP2CA is enhanced by AMBRA1
CC       (PubMed:25438055, PubMed:25803737). {ECO:0000250|UniProtKB:P01108,
CC       ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:1597196,
CC       ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,
CC       ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,
CC       ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25803737,
CC       ECO:0000269|PubMed:30158517, ECO:0000269|PubMed:8386367}.
CC   -!- PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at
CC       Thr-73 and Ser-77, leading to its degradation by the proteasome
CC       (PubMed:15103331, PubMed:17558397, PubMed:25775507, PubMed:30158517).
CC       In the nucleoplasm, ubiquitination is counteracted by USP28, which
CC       interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its
CC       deubiquitination and preventing degradation (PubMed:17558397,
CC       PubMed:17873522). In the nucleolus, however, ubiquitination is not
CC       counteracted by USP28 but by USP36, due to the lack of interaction
CC       between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the
CC       selective MYC degradation in the nucleolus (PubMed:17558397,
CC       PubMed:25775507). Also polyubiquitinated by the DCX(TRPC4AP) complex
CC       (PubMed:20551172, PubMed:29779948). Ubiquitinated by UBR5 when not
CC       forming a heterodimer with another bHLH protein, leading to its
CC       degradation: UBR5 recognizes and binds a degron that is only available
CC       upon heterodimer dissociation (PubMed:33208877, PubMed:37478862).
CC       Ubiquitinated by TRIM6 in a phosphorylation-independent manner (By
CC       similarity). {ECO:0000250|UniProtKB:P01108,
CC       ECO:0000269|PubMed:15103331, ECO:0000269|PubMed:17558397,
CC       ECO:0000269|PubMed:17873522, ECO:0000269|PubMed:20551172,
CC       ECO:0000269|PubMed:25775507, ECO:0000269|PubMed:29779948,
CC       ECO:0000269|PubMed:30158517, ECO:0000269|PubMed:33208877,
CC       ECO:0000269|PubMed:37478862}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MYC may be a cause of
CC       a form of B-cell chronic lymphocytic leukemia. Translocation
CC       t(8;12)(q24;q22) with BTG1. {ECO:0000269|PubMed:2069907}.
CC   -!- DISEASE: Burkitt lymphoma (BL) [MIM:113970]: A form of undifferentiated
CC       malignant lymphoma commonly manifested as a large osteolytic lesion in
CC       the jaw or as an abdominal mass. {ECO:0000269|PubMed:2166998,
CC       ECO:0000269|PubMed:8220424}. Note=The gene represented in this entry is
CC       involved in disease pathogenesis. Chromosomal aberrations involving MYC
CC       are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22)
CC       or t(2;8) which juxtapose MYC to one of the heavy or light chain
CC       immunoglobulin gene loci.
CC   -!- BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four
CC       Yamanaka factors. When combined, these factors are sufficient to
CC       reprogram differentiated cells to an embryonic-like state designated
CC       iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology
CC       and growth properties of ES cells and express ES cell marker genes.
CC       {ECO:0000269|PubMed:18035408}.
CC   -!- MISCELLANEOUS: Alternative translation initiation from an upstream, in-
CC       frame non-ATG (CTG) codon or a downstream ATG start site results in the
CC       production of 2 isoforms with distinct N-termini, shown in this entry
CC       as isoforms 2/3 and isoform 1, respectively.
CC       {ECO:0000305|PubMed:3277717}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative translation
CC       initiation from a CTG codon, which is translated as Met.
CC       {ECO:0000305|PubMed:3277717}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative translation
CC       initiation from a CTG codon, which is translated as Met, and
CC       alternative splicing. {ECO:0000305|PubMed:3277717}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/27/MYC";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Myc entry;
CC       URL="https://en.wikipedia.org/wiki/Myc";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L00058; AAA59882.1; -; Genomic_DNA.
DR   EMBL; L00057; AAA59882.1; JOINED; Genomic_DNA.
DR   EMBL; K00535; AAA59880.1; -; Genomic_DNA.
DR   EMBL; K00534; AAA59880.1; JOINED; Genomic_DNA.
DR   EMBL; K00535; ABW69847.1; -; Genomic_DNA.
DR   EMBL; K00534; ABW69847.1; JOINED; Genomic_DNA.
DR   EMBL; X00196; CAA25015.2; -; Genomic_DNA.
DR   EMBL; X00198; CAA25015.2; JOINED; Genomic_DNA.
DR   EMBL; X00364; CAA25106.1; -; Genomic_DNA.
DR   EMBL; V00568; CAA23831.1; -; mRNA.
DR   EMBL; K01906; AAA59881.1; -; Genomic_DNA.
DR   EMBL; K01905; AAA59881.1; JOINED; Genomic_DNA.
DR   EMBL; K02276; AAA36340.1; -; mRNA.
DR   EMBL; X00676; CAA25288.1; -; Genomic_DNA.
DR   EMBL; D10493; BAA01374.2; -; Genomic_DNA.
DR   EMBL; D10493; BAA01375.1; -; Genomic_DNA.
DR   EMBL; BT019768; AAV38573.1; -; mRNA.
DR   EMBL; AY214166; AAO21131.1; -; Genomic_DNA.
DR   EMBL; AK312883; BAG35731.1; -; mRNA.
DR   EMBL; AC103819; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW92098.1; -; Genomic_DNA.
DR   EMBL; CH471060; EAW92100.1; -; Genomic_DNA.
DR   EMBL; CH471060; EAW92101.1; -; Genomic_DNA.
DR   EMBL; BC000141; AAH00141.2; -; mRNA.
DR   EMBL; BC000917; AAH00917.2; -; mRNA.
DR   EMBL; BC058901; AAH58901.2; -; mRNA.
DR   EMBL; M13929; AAA88092.1; -; mRNA.
DR   CCDS; CCDS6359.2; -. [P01106-2]
DR   CCDS; CCDS87627.1; -. [P01106-3]
DR   PIR; A01349; TVHUM.
DR   PIR; A01350; TVHUT.
DR   RefSeq; NP_001341799.1; NM_001354870.1. [P01106-3]
DR   RefSeq; NP_002458.2; NM_002467.6. [P01106-2]
DR   PDB; 1A93; NMR; -; A=421-449.
DR   PDB; 1EE4; X-ray; 2.10 A; C/D/E/F=335-343.
DR   PDB; 1MV0; NMR; -; A=70-83.
DR   PDB; 1NKP; X-ray; 1.80 A; A/D=368-449.
DR   PDB; 2A93; NMR; -; A=421-449.
DR   PDB; 2OR9; X-ray; 2.70 A; P=425-434.
DR   PDB; 4Y7R; X-ray; 1.90 A; B=275-282.
DR   PDB; 5I4Z; X-ray; 1.95 A; A/B=365-454.
DR   PDB; 5I50; X-ray; 2.70 A; A/B=365-454.
DR   PDB; 6C4U; X-ray; 2.60 A; G/H/I/J/K/L=69-77.
DR   PDB; 6E16; X-ray; 2.40 A; A=111-140.
DR   PDB; 6E24; X-ray; 3.00 A; A=111-140.
DR   PDB; 6G6J; X-ray; 2.25 A; A/C=366-452.
DR   PDB; 6G6K; X-ray; 1.35 A; A/C=366-452.
DR   PDB; 6G6L; X-ray; 2.20 A; A/C/E/G=366-452.
DR   PDB; 7T1Y; X-ray; 2.55 A; C=250-280.
DR   PDB; 7T1Z; X-ray; 2.77 A; C=62-81.
DR   PDB; 8J2Q; X-ray; 1.92 A; A=417-427.
DR   PDB; 8OTS; EM; 3.30 A; M=351-437.
DR   PDB; 8OTT; EM; 3.30 A; M=353-405.
DR   PDB; 8Q1N; X-ray; 1.84 A; a/b=273-283.
DR   PDB; 8WLG; X-ray; 2.55 A; A=417-426.
DR   PDB; 8X8S; X-ray; 2.04 A; A=417-427.
DR   PDB; 8X8V; X-ray; 2.00 A; A=417-427.
DR   PDBsum; 1A93; -.
DR   PDBsum; 1EE4; -.
DR   PDBsum; 1MV0; -.
DR   PDBsum; 1NKP; -.
DR   PDBsum; 2A93; -.
DR   PDBsum; 2OR9; -.
DR   PDBsum; 4Y7R; -.
DR   PDBsum; 5I4Z; -.
DR   PDBsum; 5I50; -.
DR   PDBsum; 6C4U; -.
DR   PDBsum; 6E16; -.
DR   PDBsum; 6E24; -.
DR   PDBsum; 6G6J; -.
DR   PDBsum; 6G6K; -.
DR   PDBsum; 6G6L; -.
DR   PDBsum; 7T1Y; -.
DR   PDBsum; 7T1Z; -.
DR   PDBsum; 8J2Q; -.
DR   PDBsum; 8OTS; -.
DR   PDBsum; 8OTT; -.
DR   PDBsum; 8Q1N; -.
DR   PDBsum; 8WLG; -.
DR   PDBsum; 8X8S; -.
DR   PDBsum; 8X8V; -.
DR   AlphaFoldDB; P01106; -.
DR   BMRB; P01106; -.
DR   EMDB; EMD-17159; -.
DR   EMDB; EMD-17183; -.
DR   EMDB; EMD-17184; -.
DR   SMR; P01106; -.
DR   BioGRID; 110694; 3075.
DR   ComplexPortal; CPX-1123; FOXO3-MYC complex.
DR   ComplexPortal; CPX-514; c-MYC-BIN1 complex.
DR   ComplexPortal; CPX-91; MYC-MAX transcriptional activator complex.
DR   CORUM; P01106; -.
DR   DIP; DIP-28143N; -.
DR   FunCoup; P01106; 3942.
DR   IntAct; P01106; 843.
DR   MINT; P01106; -.
DR   STRING; 9606.ENSP00000478887; -.
DR   BindingDB; P01106; -.
DR   ChEMBL; CHEMBL1250348; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB01093; Dimethyl sulfoxide.
DR   DrugBank; DB03756; Doconexent.
DR   DrugBank; DB08813; Nadroparin.
DR   GlyConnect; 426; 1 O-GlcNAc glycan (1 site).
DR   GlyCosmos; P01106; 1 site, 1 glycan.
DR   GlyGen; P01106; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P01106; -.
DR   PhosphoSitePlus; P01106; -.
DR   BioMuta; MYC; -.
DR   DMDM; 127619; -.
DR   jPOST; P01106; -.
DR   MassIVE; P01106; -.
DR   PaxDb; 9606-ENSP00000479618; -.
DR   PeptideAtlas; P01106; -.
DR   ProteomicsDB; 36826; -.
DR   ProteomicsDB; 51318; -. [P01106-1]
DR   ProteomicsDB; 51319; -. [P01106-2]
DR   Pumba; P01106; -.
DR   ABCD; P01106; 7 sequenced antibodies.
DR   Antibodypedia; 3520; 4268 antibodies from 54 providers.
DR   DNASU; 4609; -.
DR   Ensembl; ENST00000377970.6; ENSP00000367207.3; ENSG00000136997.22. [P01106-1]
DR   Ensembl; ENST00000524013.2; ENSP00000430235.2; ENSG00000136997.22. [P01106-3]
DR   Ensembl; ENST00000621592.8; ENSP00000478887.2; ENSG00000136997.22. [P01106-2]
DR   Ensembl; ENST00000652288.1; ENSP00000499105.1; ENSG00000136997.22. [P01106-1]
DR   Ensembl; ENST00000707113.1; ENSP00000516742.1; ENSG00000136997.22. [P01106-1]
DR   Ensembl; ENST00000707114.1; ENSP00000516743.1; ENSG00000136997.22. [P01106-1]
DR   Ensembl; ENST00000707115.1; ENSP00000516744.1; ENSG00000136997.22. [P01106-1]
DR   Ensembl; ENST00000707116.1; ENSP00000516745.1; ENSG00000136997.22. [P01106-1]
DR   GeneID; 4609; -.
DR   KEGG; hsa:4609; -.
DR   MANE-Select; ENST00000621592.8; ENSP00000478887.2; NM_002467.6; NP_002458.2.
DR   UCSC; uc064qdj.1; human. [P01106-2]
DR   AGR; HGNC:7553; -.
DR   CTD; 4609; -.
DR   DisGeNET; 4609; -.
DR   GeneCards; MYC; -.
DR   HGNC; HGNC:7553; MYC.
DR   HPA; ENSG00000136997; Tissue enhanced (adipose tissue, skin).
DR   MalaCards; MYC; -.
DR   MIM; 113970; phenotype.
DR   MIM; 190080; gene.
DR   neXtProt; NX_P01106; -.
DR   OpenTargets; ENSG00000136997; -.
DR   Orphanet; 543; Burkitt lymphoma.
DR   Orphanet; 480541; High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA31353; -.
DR   VEuPathDB; HostDB:ENSG00000136997; -.
DR   eggNOG; KOG2483; Eukaryota.
DR   GeneTree; ENSGT00940000155285; -.
DR   HOGENOM; CLU_052560_0_0_1; -.
DR   InParanoid; P01106; -.
DR   OMA; FPYPLHD; -.
DR   OrthoDB; 5964374at2759; -.
DR   PAN-GO; P01106; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P01106; -.
DR   TreeFam; TF106001; -.
DR   BioCyc; MetaCyc:ENSG00000136997-MONOMER; -.
DR   PathwayCommons; P01106; -.
DR   Reactome; R-HSA-1362277; Transcription of E2F targets under negative control by DREAM complex.
DR   Reactome; R-HSA-201556; Signaling by ALK.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8866911; TFAP2 (AP-2) family regulates transcription of cell cycle factors.
DR   Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   Reactome; R-HSA-9818749; Regulation of NFE2L2 gene expression.
DR   SignaLink; P01106; -.
DR   SIGNOR; P01106; -.
DR   BioGRID-ORCS; 4609; 858 hits in 1206 CRISPR screens.
DR   CD-CODE; 02CD31EB; Synthetic Condensate 000174.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; BADFB975; Synthetic Condensate 000187.
DR   ChiTaRS; MYC; human.
DR   EvolutionaryTrace; P01106; -.
DR   GeneWiki; Myc; -.
DR   GenomeRNAi; 4609; -.
DR   Pharos; P01106; Tchem.
DR   PRO; PR:P01106; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P01106; protein.
DR   Bgee; ENSG00000136997; Expressed in upper leg skin and 182 other cell types or tissues.
DR   ExpressionAtlas; P01106; baseline and differential.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0000791; C:euchromatin; IEA:Ensembl.
DR   GO; GO:0071943; C:Myc-Max complex; IPI:ComplexPortal.
DR   GO; GO:0016604; C:nuclear body; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0090571; C:RNA polymerase II transcription repressor complex; IPI:ComplexPortal.
DR   GO; GO:0005819; C:spindle; IEA:Ensembl.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:UniProt.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1905761; F:SCF ubiquitin ligase complex binding; IPI:DisProt.
DR   GO; GO:0001221; F:transcription coregulator binding; IPI:UniProtKB.
DR   GO; GO:0140537; F:transcription regulator activator activity; IEP:DisProt.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:1990863; P:acinar cell proliferation; IEA:Ensembl.
DR   GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:CAFA.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IEP:UniProtKB.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0051276; P:chromosome organization; IDA:UniProtKB.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:CAFA.
DR   GO; GO:0044346; P:fibroblast apoptotic process; TAS:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0051782; P:negative regulation of cell division; IDA:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:BHF-UCL.
DR   GO; GO:0045656; P:negative regulation of monocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0060633; P:negative regulation of transcription initiation by RNA polymerase II; IDA:UniProt.
DR   GO; GO:0001866; P:NK T cell proliferation; IEA:Ensembl.
DR   GO; GO:0043473; P:pigmentation; IEA:Ensembl.
DR   GO; GO:1904699; P:positive regulation of acinar cell proliferation; IEA:Ensembl.
DR   GO; GO:0002904; P:positive regulation of B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA.
DR   GO; GO:1902255; P:positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB.
DR   GO; GO:0090096; P:positive regulation of metanephric cap mesenchymal cell proliferation; ISS:UniProtKB.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:ARUK-UCL.
DR   GO; GO:0032206; P:positive regulation of telomere maintenance; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0016485; P:protein processing; IEA:Ensembl.
DR   GO; GO:0032986; P:protein-DNA complex disassembly; IDA:CAFA.
DR   GO; GO:0010564; P:regulation of cell cycle process; IDA:ComplexPortal.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:1904672; P:regulation of somatic stem cell population maintenance; ISS:UniProtKB.
DR   GO; GO:0032204; P:regulation of telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0043279; P:response to alkaloid; IEA:Ensembl.
DR   GO; GO:0070848; P:response to growth factor; TAS:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:UniProtKB.
DR   GO; GO:0016072; P:rRNA metabolic process; IMP:UniProtKB.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:Ensembl.
DR   CDD; cd11458; bHLHzip_c-Myc; 1.
DR   DisProt; DP00260; -.
DR   FunFam; 4.10.280.10:FF:000019; Myc proto-oncogene protein; 1.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   IDEAL; IID00012; -.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR003327; Myc-LZ.
DR   InterPro; IPR050433; Myc_transcription_factors.
DR   InterPro; IPR002418; Tscrpt_reg_Myc.
DR   InterPro; IPR012682; Tscrpt_reg_Myc_N.
DR   PANTHER; PTHR45851; MYC PROTO-ONCOGENE; 1.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF02344; Myc-LZ; 1.
DR   Pfam; PF01056; Myc_N; 1.
DR   PIRSF; PIRSF001705; Myc_protein; 1.
DR   PRINTS; PR00044; LEUZIPPRMYC.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative initiation;
KW   Alternative splicing; Chromosomal rearrangement; Chromosome; Cytoplasm;
KW   DNA-binding; Glycoprotein; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Proteomics identification; Proto-oncogene; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..454
FT                   /note="Myc proto-oncogene protein"
FT                   /id="PRO_0000127293"
FT   DOMAIN          369..421
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          219..310
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          369..382
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          383..421
FT                   /note="Helix-loop-helix motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          428..449
FT                   /note="Leucine-zipper"
FT   MOTIF           115..123
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000269|PubMed:34342803"
FT   MOTIF           370..379
FT                   /note="UBR5-degron"
FT                   /evidence="ECO:0000269|PubMed:37478862"
FT   COMPBIAS        222..252
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        266..278
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        281..293
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         23
FT                   /note="Phosphothreonine; by RAF; in vitro"
FT                   /evidence="ECO:0000269|PubMed:9315742"
FT   MOD_RES         73
FT                   /note="Phosphothreonine; by GSK3; alternate"
FT                   /evidence="ECO:0000269|PubMed:15103331,
FT                   ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:30158517,
FT                   ECO:0000269|PubMed:8386367, ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         77
FT                   /note="Phosphoserine; by DYRK2, GSK3 and CDK2"
FT                   /evidence="ECO:0000269|PubMed:15103331,
FT                   ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,
FT                   ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329,
FT                   ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25803737,
FT                   ECO:0000269|PubMed:30158517, ECO:0000269|PubMed:8386367,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         86
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         96
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         158
FT                   /note="N6-acetyllysine; by PCAF; alternate"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   MOD_RES         163
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         166
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         172
FT                   /note="N6-acetyllysine; by PCAF"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         176
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         290
FT                   /note="N6-acetyllysine; by PCAF"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   MOD_RES         308
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         330
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         332
FT                   /note="N6-acetyllysine; by PCAF"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   MOD_RES         338
FT                   /note="N6-acetyllysine; by PCAF"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   MOD_RES         344
FT                   /note="Phosphoserine; by PIM2; in vitro"
FT                   /evidence="ECO:0000250|UniProtKB:P01108"
FT   MOD_RES         359
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:30158517"
FT   MOD_RES         386
FT                   /note="N6-acetyllysine; by PCAF"
FT                   /evidence="ECO:0000269|PubMed:16126174"
FT   CARBOHYD        73
FT                   /note="O-linked (GlcNAc) threonine; alternate"
FT                   /evidence="ECO:0000269|PubMed:7642555"
FT                   /id="CAR_000033"
FT   CROSSLNK        67
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        158
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        163
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        313
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..15
FT                   /note="Missing (in isoform 1)"
FT                   /id="VSP_061778"
FT   VAR_SEQ         10..11
FT                   /note="QQ -> Q (in isoform 3)"
FT                   /id="VSP_061779"
FT   VARIANT         26
FT                   /note="N -> S (in dbSNP:rs4645959)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_016327"
FT   VARIANT         54
FT                   /note="E -> D (in a Burkitt lymphoma sample;
FT                   dbSNP:rs121918684)"
FT                   /evidence="ECO:0000269|PubMed:6419122,
FT                   ECO:0000269|PubMed:8220424"
FT                   /id="VAR_063384"
FT   VARIANT         72
FT                   /note="P -> S (in a Burkitt lymphoma sample;
FT                   dbSNP:rs28933407)"
FT                   /evidence="ECO:0000269|PubMed:8220424"
FT                   /id="VAR_063385"
FT   VARIANT         74
FT                   /note="P -> A (in a Burkitt lymphoma sample;
FT                   dbSNP:rs121918685)"
FT                   /evidence="ECO:0000269|PubMed:8220424"
FT                   /id="VAR_063386"
FT   VARIANT         101
FT                   /note="N -> T (in a Burkitt lymphoma sample;
FT                   dbSNP:rs121918683)"
FT                   /evidence="ECO:0000269|PubMed:8220424"
FT                   /id="VAR_063387"
FT   VARIANT         175
FT                   /note="G -> C (in dbSNP:rs4645960)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_016328"
FT   VARIANT         185
FT                   /note="V -> I (in dbSNP:rs4645961)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_016329"
FT   VARIANT         337
FT                   /note="A -> V (in dbSNP:rs4645968)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_016330"
FT   MUTAGEN         73
FT                   /note="T->A: Impairs interaction with FBXW7 and subsequent
FT                   degradation by the proteasome. Normal inhibition of
FT                   Ras-induced senescence."
FT                   /evidence="ECO:0000269|PubMed:15103331,
FT                   ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,
FT                   ECO:0000269|PubMed:20713526"
FT   MUTAGEN         77
FT                   /note="S->A: Impairs interaction with FBXW7 and subsequent
FT                   degradation by the proteasome. Impaired inhibition of
FT                   Ras-induced senescence. Abolishes phosphorylation by DYRK2,
FT                   and subsequent phosphorylation by GSK3B at Thr-73."
FT                   /evidence="ECO:0000269|PubMed:15103331,
FT                   ECO:0000269|PubMed:17558397, ECO:0000269|PubMed:19966300,
FT                   ECO:0000269|PubMed:20713526, ECO:0000269|PubMed:22307329"
FT   MUTAGEN         77
FT                   /note="S->D: Phospho-mimetic mutant; abolished regulation
FT                   by AMBRA1."
FT                   /evidence="ECO:0000269|PubMed:25438055"
FT   MUTAGEN         450
FT                   /note="R->K: Abolished ubiquitination and degradation by
FT                   the DCX(TRPC4AP) complex."
FT                   /evidence="ECO:0000269|PubMed:29779948"
FT   CONFLICT        2
FT                   /note="D -> N (in Ref. 9; BAA01374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        6
FT                   /note="V -> E (in Ref. 9; BAA01374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        21..22
FT                   /note="SF -> TI (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        25
FT                   /note="R -> K (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71
FT                   /note="L -> LL (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        77
FT                   /note="S -> P (in Ref. 7; CAA25288)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103
FT                   /note="G -> D (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        107
FT                   /note="S -> N (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        129
FT                   /note="S -> N (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        135
FT                   /note="D -> G (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        186
FT                   /note="C -> S (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="S -> R (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="S -> A (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        255
FT                   /note="L -> F (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        260
FT                   /note="P -> S (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   HELIX           113..118
FT                   /evidence="ECO:0007829|PDB:6E16"
FT   HELIX           119..121
FT                   /evidence="ECO:0007829|PDB:6E16"
FT   HELIX           366..393
FT                   /evidence="ECO:0007829|PDB:6G6K"
FT   HELIX           397..399
FT                   /evidence="ECO:0007829|PDB:6G6K"
FT   HELIX           407..450
FT                   /evidence="ECO:0007829|PDB:6G6K"
SQ   SEQUENCE   454 AA;  50565 MW;  8B4107BB740689E5 CRC64;
     MDFFRVVENQ QPPATMPLNV SFTNRNYDLD YDSVQPYFYC DEEENFYQQQ QQSELQPPAP
     SEDIWKKFEL LPTPPLSPSR RSGLCSPSYV AVTPFSLRGD NDGGGGSFST ADQLEMVTEL
     LGGDMVNQSF ICDPDDETFI KNIIIQDCMW SGFSAAAKLV SEKLASYQAA RKDSGSPNPA
     RGHSVCSTSS LYLQDLSAAA SECIDPSVVF PYPLNDSSSP KSCASQDSSA FSPSSDSLLS
     STESSPQGSP EPLVLHEETP PTTSSDSEEE QEDEEEIDVV SVEKRQAPGK RSESGSPSAG
     GHSKPPHSPL VLKRCHVSTH QHNYAAPPST RKDYPAAKRV KLDSVRVLRQ ISNNRKCTSP
     RSSDTEENVK RRTHNVLERQ RRNELKRSFF ALRDQIPELE NNEKAPKVVI LKKATAYILS
     VQAEEQKLIS EEDLLRKRRE QLKHKLEQLR NSCA
//
